Shares of vaccine producers' stocks are trading higher Wednesday on reports indicating disease experts predict a small rise in COVID-19 cases this summer.
The Details:
According to a report from NBC News, experts predict a small rise in COVID-19 cases as a newly dominant strain spreads. The new strain, KP.2, represents 28% of COVID-19 infections in the U.S. and experts believe its mutations have made the variant more immune evasive.
Much remains unknown about the KP.2 variant, however, research from Japan suggests current COVID-19 vaccines may be less effective against KP.2 than against previous variants.
The same research also suggests KP.2 might be less efficient at infecting cells, making the new variant more difficult to transmit and less likely to cause severe symptoms. Experts are predicting a rise in COVID-19 cases, however, they expect the rise to be smaller than in previous years.
Shares of vaccine-makers, including BioNTech SE (NASDAQ:BNTX) and Novavax, Inc. (NASDAQ:NVAX), are climbing as COVID-19 headlines return to the spotlight.
Moderna, Inc. (NASDAQ:MRNA) shares are trading at new 52-week highs following the report, and Pfizer, Inc. (NYSE:PFE) shares are also moving higher.
BNTX, NVAX, MRNA, PFE Price Action: According to Benzinga Pro, BioNTech shares are up 8.58% at $99.97, Novavax shares are up 7.38% at $16.01, Moderna shares are up 10.2% at $158.29 and Pfizer shares are up 2.45% at $29.26 at the time of publication Wednesday.
疫苗生產商的股票週三上漲,原因是有報道稱,疾病專家預測今年夏天 COVID-19 病例將小幅上升。
細節:
根據美國全國廣播公司新聞的報道,專家預測,隨着一種新的占主導地位的菌株傳播,COVID-19 病例將小幅增加。新菌株KP.2佔美國 COVID-19 感染的28%,專家認爲其突變使該變種更具免疫逃避能力。
關於KP.2變體還有很多未知數,但是,日本的研究表明,目前的 COVID-19 疫苗對KP.2的有效性可能不如對以前的變體。
同一項研究還表明,KP.2感染細胞的效率可能較低,這使得新變種更難傳播,也不太可能引起嚴重症狀。專家預測,COVID-19 病例將增加,但是,他們預計增幅將小於往年。
隨着 COVID-19 的頭條新聞重新成爲人們關注的焦點,包括BioNTech SE(納斯達克股票代碼:BNTX)和Novavax, Inc.(納斯達克股票代碼:NVAX)在內的疫苗生產商的股價正在攀升。
報告發布後,摩德納公司(納斯達克股票代碼:MRNA)股價創下52周新高,輝瑞公司(紐約證券交易所代碼:PFE)的股價也在走高。
BNTX、NVAX、MRNA、PFE價格走勢:根據Benzinga Pro的數據,BioNTech股價上漲8.58%,至99.97美元,Novavax股價上漲7.38%,至16.01美元,Moderna股價上漲10.2%,至158.29美元,輝瑞股價上漲2.45%,至29.26美元。